CD8A and pancreatic neoplasm: Similarly, using the PI3Kα inhibitor CYH33 in pancreatic cancer mouse models enhances tumor microenvironment fatty acid metabolism, activating CD8+ T cells and triggering anti-tumor immunity [51].